Casandra
Casandra Test Code QD86044Version 1 (DRAFT)
Performing Lab
CEBPA Mutation Analysis, Extracted DNA
Clinical Use
Order TestUse
The CEBPA gene, a myeloid transcription factor, is mutated in a subset of acute myeloid leukemia (AML), particularly in patients with cytogenetically normal karyotype (CN‑AML). Presence of CEBPA mutations has been associated with a favorable prognosis compared to other CN‑AML groups. Testing for CEBPA mutation, along with NPM1, is recommended for all patients with CN‑AML.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
Methodology
NGS
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Whole Blood
Volume
5 mL preferred; 2 mL minimum
Minimum Volume
Not provided
Container
EDTA (lavender‑top) tube
Similar Tests
Other tests from different labs that may be relevant
CEBPA Mutation Analysis
Labcorp
CEBPA Mutation Analysis
NeoGenomics
NPM1 Mutation Analysis
Labcorp
NPM1 Mutation Analysis
NeoGenomics
Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing
ARUP Laboratories
NPM1 Mutation Detection by RT-PCR, Quantitative
ARUP Laboratories
Nucleophosmin (NPM1) Mutation Analysis, Varies
Mayo Clinic Lab
NPM1 MRD Analysis
NeoGenomics
Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel
ARUP Laboratories
Myeloid Malignancies Mutation and Copy Number Variation Panel by Next Generation Sequencing
ARUP Laboratories